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The rationale of this study is based on the fact that, both
proteinuria and elevated asymmetric dimethyl arginine
(ADMA) levels have been linked to the progression of
vascular disease. Currently, there is not enough knowledge
about any association between the levels of proteinuria and
ADMA levels. Seventy-eight non-diabetic patients (42 men,
36women, mean age of 26.175.2 years) with proteinuria
having normal glomerular filtration rate were enrolled along
with 38 healthy subjects (20men, 18women, mean age of
26.975.9 years). Proteinuria was below 3.5 g/day in 40
patients and above 3.5 g/day in 38 patients. Both groups had
similar age, gender, and body mass index distributions.
Serum ADMA, symmetric dimethyl arginine (SDMA),
immunoreactive insulin, and high sensitivity C reactive
protein (hsCRP) levels were measured. Insulin resistance was
determined by homeostasis model assessment (HOMA).
Serum ADMA, SDMA, insulin, hsCRP levels, and HOMA
indexes were significantly higher in patients than in healthy
control subjects. The above parameters were higher in the
nephrotic range proteinuria group when compared to
patients having protein levels below 3.5 g/day. There were
significant correlations between the levels of proteinuria and
the above parameters. According to the regression analysis,
levels of proteinuria and hsCRP were significant determinants
of serum ADMA levels. Our results indicate that, independent
of other risk factors, ADMA is directly associated with
proteinuria. Further studies are recommended to find out
whether elevated ADMA levels are implicated in the high
cardiovascular risk of proteinuric nephropathies.
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Proteinuria is now recognized as an important cardiovascular
risk factor not only in disease states such as diabetes mellitus
and hypertension,1,2 but also in the general population3,4
where it has prognostic implications also within the normal
range of albumin excretion.5 Furthermore, it is well
demonstrated that there is a dose–response relationship
between proteinuria and cardiovascular risk factors,4 an
observation in keeping with clinical studies showing that
vascular function is impaired in patients with microalbumi-
nuria6,7 and particularly so in those with frank proteinuria.8
Inflammation, insulin resistance, and dyslipidemia have been
implicated in cardiovascular damage in proteinuric pa-
tients.8–10 Yet, the exact pathophysiological mechanisms
responsible for the high cardiovascular risk of these patients
are still unclear.11
The endogeneous inhibitor of nitric oxide synthase,
asymmetric dimethyl arginine (ADMA) is considered as a
likely causative factor in endothelial dysfunction in hu-
mans.12,13 The relationship between ADMA and proteinuria
has not been thoroughly analyzed. Fliser et al.14 reported that
plasma ADMA levels were increased and positively correlated
with proteinuria in patients with renal failure. As altered
renal function is associated with the elevation of plasma
ADMA levels,15–18 we performed a survey to study the
association between these two risk factors in a well-selected
series of patients with proteinuric nephropathies and normal
glomerular filtration rate (GFR).
RESULTS
Clinical characteristics
The clinical and laboratory characteristics of patients and
healthy control subjects are shown in Table 1. The etiology of
proteinuria is also reported in Table 2. There were no
significant differences between patients and controls in terms
of age, body mass index (BMI), blood urea, serum creatinine,
GFR, systolic and diastolic blood pressure (BP), total
cholesterol, high-density lipoprotein cholesterol, low-density
lipoprotein cholesterol, and triglyceride levels. As expected,
total protein concentration and serum albumin were lower in
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patients than in controls, but these differences did not
achieve statistical significance. Patients had significantly
higher levels of ADMA, symmetric dimethyl arginine
(SDMA), insulin and high sensitivity C reactive protein
(hsCRP) concentrations, and homeostasis model assessment
(HOMA) indexes than controls (Po0.001 for all).
The characteristics of Group I (proteinuria o3.5 g/day)
and Group II patients (proteinuria 43.5 g/day) are also
presented in Table 1. No significant differences were observed
between these subgroups as for age, BMI, sex, blood urea,
creatinine, systolic and diastolic BPs, total cholesterol, high-
density lipoprotein cholesterol, low-density lipoprotein
cholesterol, and triglyceride levels. Group II patients had
not only higher serum ADMA levels but also higher
(Po0.001) levels of hsCRP (12.471.6 mg/l) than Group I
patients (7.274.2 mg/l) (Figure 1). Also, the fasting glucose,
insulin, HOMA index, and SDMA levels of patients were
significantly higher and total protein, albumin levels were
significantly lower, in Group II when compared to those of
Group I patients.
Of note, serum ADMA concentrations in Group I patients
without nephrotic range proteinuria were also significantly
higher than those of healthy controls (1.4870.32 vs
1.0870.13 mmol/l, respectively, Po0.001) (Figure 1).
Table 1 | Clinical and laboratory features of the patient and control groups
Controls
(n=38)
Patients
(n=78)
Group I proteinuria
(o3.5 g/day) (n=40)
Group II proteinuria
(43.5 g/day) (n=38) P* P**
Age (years) 2676 2675 2574 2576 0.400w 0.695
Sex (M/F) 20/18 42/36 22/18 20/18 0.356z 0.436
GFR (ml/min/1.73 m2) 11777 11579 10679 10577 0.186w 0.165
Serum creatinine (mg/dl) 0.8670.2 0.7970.2 0.7870.2 0.8070.2 0.225w 0.385
Blood urea (mg/dl) 35710 35710 35710 34710 0.852w 0.674
Total protein (g/dl) 6.770.4 5.771.1 6.870.4 4.170.4 0.060w o0.001
Serum albumin (g/dl) 4.170.3 3.071.1 3.770.3 2.370.4 0.072w o0.001
Systolic BP (mm Hg) 13076 130714 12978 13078 0.332y 0.577
Diastolic BP (mm Hg) 8374 8374 8374 8373 0.764y 0.208
Total cholesterol (mg/dl) 179718 177719 174716 175717 0.211y 0.372
Triglycerides (mg/dl) 120714 127723 126722 125724 0.119w 0.245
LDL cholesterol (mg/dl) 103714 105716 105715 107717 0.678w 0.649
HDL cholesterol (mg/dl) 4276 4075 4074 3775 0.267w 0.908
BMI (kg/m2) 2672 2772 2672 2772 0.834w 0.813
Amount of proteinuria (g/day) 0.0970.03 3.872.8 1.370.4 6.371.6 o0.001w o0.001
HsCRP (mg/l) 1.870.6 9.774.0 7.274.2 12.471.6 o0.001w o0.001
FPG (mg/dl) 7879 7978 8077 7978 0.871w o0.001
Insulin (mIU/ml) 672 1274 972 1474 o0.001w o0.001
HOMA 1.270.3 2.370.8 1.870.5 2.870.4 o0.001w o0.001
SDMA (mmol/l) 0.9070.23 1.8170.69 1.4570.38 2.1870.76 o0.001w o0.001
ADMA (mmol/l) 1.0870.13 1.9270.65 1.4870.32 2.3970.58 o0.001w o0.001
ADMA, asymmetric dimethyl arginine; BMI, body mass index; BP, blood pressure; FPG, fasting plasma glucose; F, female; GFR, glomerular filtration rate; HDL, high-density
lipoprotein; HOMA, homeostasis model assessment; hsCRP, high sensitive C reactive protein; LDL, low-density lipoprotein; M, male; SDMA, symmetric dimethyl arginine.
*Patients versus control. These variables are matched for in analyses. wt-test, yMann–Whitney U-test, and zw2 test.
**t-test; According to the severity of proteinuria (between Group I and Group II).
Table 2 | Etiology of proteinuria according to pathologic
diagnosis
Etiology of proteinuria
Proteinuria
(o3.5 g/day)
Group I (n=40)
Proteinuria
(X3.5 g/day)
Group II (n=38)
FSGS 14 14
IgAN 3 6
Secondary FSGS 5 —
Membranous
nephropathy
9 —
MPGN 1 —
Minimal mesengial
proliferation
6 —
Lupus nephritis 2 2
Minimal change disease — 16
FSGS, focal segmental glomerulosclerosis; IgAN, IgA nephropathy; MPGN, membrano-
proliferative glomerulonephritis.
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Figure 1 | ADMA and hsCRP levels in control subjects and
patients with and without nephrotic range proteinuria.
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Associations of serum ADMA and SDMA concentrations with
proteinuria, hsCRP, and insulin resistance
In the aggregate (Group I and Group II patients), serum
ADMA concentrations were associated with proteinuria levels
(r¼ 0.78, Po0.001) (Figure 2). Serum ADMA concentra-
tions were also positively correlated with serum insulin levels
(r¼ 0.37, P¼ 0.001), HOMA indexes (r¼ 0.32, P¼ 0.004)
and hsCRP levels (r¼ 0.61, Po0.001), and GFR (r¼0.360,
P¼ 0.001) and negatively correlated with serum albumin
levels (r¼0.66, Po0.001).
Serum SDMA concentrations were negatively correlated
with GFR (r¼0.225, P¼ 0.048), hsCRP (r¼ 0.401,
Po0.001), and proteinuria (r¼ 0.497, Po0.001) (Figure 2).
Other than ADMA and SDMA levels, the amount of
proteinuria levels were also correlated with serum insulin
(r¼ 0.53, Po0.001), HOMA (r¼ 0.55, Po0.001), and
hsCRP levels (r¼ 0.64, Po0.001).
Multiple regression analysis
In order to clarify whether the association between ADMA
and proteinuria was independent of other risk factors, we
undertook a multiple regression analysis considering demo-
graphic factors (age and sex) and covariates that resulted to
be associated with proteinuria in the univariate analysis
(hsCRP and HOMA index) as well as the GFR. In this model,
the association between ADMA and proteinuria was weaker
than that observed in univariate analysis but still significant
(Table 3). Levels of proteinuria (b¼ 649, Po0.001) and
hsCRP (b¼ 0.199, P¼ 0.033) were independently related to
ADMA levels (Figure 3).
As expected, because of the characteristics of selected
patients, further adjustments for serum cholesterol and
systolic BP did not materially change the strength of the
association between ADMA and proteinuria.
DISCUSSION
The risk of cardiovascular events is increased at an early stage
in patients with renal disease.19 It was shown that even mild
renal dysfunction and/or the presence of albuminuria is
associated with increased cardiovascular mortality and
morbidity.3,4,20 Several potential causative factors have been
suggested to be responsible for this outcome, including
endothelial dysfunction, vascular calcification, oxidative
stress, and inflammation.9,10,21 Endothelial dysfunction is
currently considered a critical step for the development of
atherosclerosis.22 Albuminuria is considered as a marker of
renal and systemic vascular damage.6,7,23 Paisley et al.23 have
shown that endothelial dysfunction is present in patients with
asymptomatic proteinuria and attributed this alteration to
altered regulation of nitric oxide system. On the other hand,
dyslipidemia was implicated in the impaired endothelial
functions of patients with nephrotic proteinuria.8 Our study
shows that ADMA, a competitive nitric oxide synthase
inhibitor which seems to be involved in endothelial
dysfunction in essential hypertension24 and which is
increased in the early stages of chronic kidney disease
(CKD),23 is strongly associated with proteinuria. Impor-
tantly, our findings obtained in a study population without
overt dyslipidemia show that the link between ADMA and
proteinuria in CKD is independent of hypercholesterolemia,
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Figure 2 | The scatter plot showing the relationship between
SDMA and proteinuria.
Table 3 | Analysis of association between proteinuria and
some different parameters by univariate and multivariate
linear regression
Parameters Univariate b (P) Multivariatea b (P)
ADMA (mmol/l) 0.78 (o0.001) 0.59 (o0.001)
HOMA 0.55 (o0.001) 0.29 (o0.001)
hsCRP (mg/l) 0.62 (o0.001) 0.15 (0.068)
GFR (ml/min/1.73 m2) 0.35 (0.002) —
SBP (mm Hg) 0.03 (0.823) —
Total cholesterol (mg/dl) 0.1 (0.388) —
Age (year) 0.23 (0.145) —
Sex 0.07 (0.555) —
ADMA, asymmetric dimethyl arginine; GFR, glomerular filtration rate; HOMA,
homeostasis model assessment; hsCRP, high sensitive C reactive protein; SBP,
systolic blood pressure.
aTerminal model=0.593ADMA+0.295HOMA+0.148hsCRP.
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Figure 3 | The scatter plot showing the relationship between
ADMA with hsCRP and proteinuria.
Kidney International (2006) 70, 781–787 783
K Caglar et al.: ADMA and proteinuria in CKD o r i g i n a l a r t i c l e
that is, a typical finding in nephrotic syndrome and a factor
which per se may increase serum ADMA levels.25
ADMA is the major inhibitor of nitric oxide biosynthesis
and its elevation is associated with endothelial dysfunction.12
Increased plasma concentrations of ADMA have been
described mainly in renal failure.15,16 Numerous other
conditions including diabetes mellitus, hypercholesterolemia,
hypertension, cardiac ischemia, and congestive heart failure
have been described in association with high ADMA
levels.26–30 Our findings indicate that proteinuria is another
factor strongly associated with high ADMA. A relationship
between ADMA and proteinuria was noted in a recent cohort
study by Fliser et al.14 in patients with CKD and mild
proteinuria (average 24 h protein excretion 0.9 g) and mild to
moderate CKD. The strength of this association was much
weaker (r¼ 0.18) than that observed in the present study
(r¼ 0.77), which dealt with patients with normal GFR
(average 115 ml/min) and more severe proteinuria (average
3.7 g/24 h). Thus, our data suggest that proteinuria is an
important determinant of ADMA at a very early stage of
renal disease and that this association may be confounded by
reduced renal excretion of this dimethylarginine when renal
insufficiency supervenes.
ADMA interacts in a complex way with traditional and
non-traditional risk factors.31,32 Proteinuria is now consid-
ered as a major cardiovascular risk factor,3,4 but the
relationship between ADMA and proteinuria has hitherto
received little attention. The question is of relevance because
mechanism(s) conducive to cardiovascular risk in proteinuric
patients are still incompletely understood. Increased ADMA
appears to be a potential link between proteinuria and
endothelial dysfunction and atherosclerotic complications. It
is important to note that, in our study, ADMA levels
increased in parallel to the elevation of insulin levels, HOMA,
and hsCRP. Previously, the association between insulin
sensitivities and ADMA levels was reported in healthy
adults.32 The data about the relationship between ADMA
and inflammation were also mentioned both in patients with
end-stage renal disease and chronic cytomegalovirus infec-
tion.33,34 These associations may potentially confound the
interpretation of the ADMA proteinuria link because
proteinuria per se is also associated both with high CRP
and reduced insulin sensitivity. Although the link between
ADMA and proteinuria remains to be specifically investigated
in mechanistic and intervention studies, the multiple
regression analysis showing that proteinuria is an indepen-
dent correlate of ADMA suggests that this link is not the
mere result of the confounding effect of inflammation and
insulin resistance.
There may be several scenarios to explain the relationship
between proteinuria and ADMA elevation. Proteinuria is a
state of increased protein turnover. When proteins undergo
proteolysis, free methylarginines (ADMA and SDMA) are
released as recently described for states of increased protein
metabolism and insulin resistance.35 The association between
the proteinuria and SDMA levels in the present study
strengthens this notion. In addition, the positive correlation
between the ADMA and albumin levels may point out
another mechanism of high ADMA levels, as ADMA is
protein bound to some degree.36 On the other hand, kidney
is a fundamental organ for the clearance of ADMA both
because it excretes ADMA and contributes to metabolic
degradation of this substance by the enzyme dimethyl
arginine dimethylaminohydrolase, which is abundantly
expressed in renal endothelial and tubule cells.31 Protein
overload exerts noxious effects in the renal tubule,37 and it
can be hypothesized that such an overload alters the
expression of dimethyl arginine dimethylaminohydrolase
thereby favoring ADMA accumulation. Recently, Kielstein
et al.38 showed that short-term elevation of ADMA levels
decrease the renal perfusion. Along with the present data, we
may put forward another hypothesis, a vicious cycle,
referring to impaired renal functions owing to proteinuria-
induced ADMA elevation, which then causes insulin
resistance and perhaps dimethyl arginine dimethylamino-
hydrolase inactivity leading to a further increase in ADMA
levels. The drugs conventionally prescribed to reduce
proteinuria have been shown to reduce ADMA levels in
hypertensive patients,39,40 whereas there are no data in
proteinuria. Thus, it will be interesting to assess whether
reducing proteinuria is associated with a parallel decrease in
plasma ADMA levels.
Insulin resistance and hyperinsulinemia in patients with
incipient renal disease have already been reported.41 Ritz
et al. have shown that insulin sensitivity is diminished in
some patients with normal GFR.41 Thus, our data confirm
and extend these observations because we found that
proteinuria explains about 9% (ADMA – HOMA, r¼ 0.32)
of insulin resistance in patients with CKD.
This study has limitations. First, the cross-sectional nature
of our observations preclude cause–effect inferences about the
strong, intriguing links between proteinuria, ADMA, SDMA,
insulin resistance, and inflammation unraveled in the present
study. Secondly, our protocol did not contemplate measure-
ments of endothelial function, information which could have
provided useful elements to improve the interpretation of
our data. Yet, the internal consistency and the strength of the
associations of ADMA with proteinuria, insulin resistance,
and inflammation that emerged from our study form a
convincing basis for designing cohort and intervention
studies aimed at testing whether ADMA is implicated in
proteinuria and in cardiovascular complications in patients
with CKD.
To conclude, our data indicate that patients with
proteinuria have higher ADMA levels along with impaired
insulin sensitivity and inflammation. Proteinuria levels
increase in parallel with the severity of the ADMA, which
appears to be an independent determinant of proteinuria
levels. These associations suggest that high ADMA may be
implicated in the high cardiovascular risk of patients with
proteinuria. Mechanistic and intervention studies are needed
to test the hypothesis generated by our observations.
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MATERIALS AND METHODS
Patients
The Gu¨lhane School of Medicine, Department of Nephrology, serves
an area of 2 million residents. The outpatient clinic of this renal unit
is an established tertiary referral center with 1200 patients/year
being evaluated for the presence of renal diseases, mostly untreated
or treated with antihypertensive agents whenever required. It is local
policy that all referred patients with a confirmed suspicion of
glomerular or systemic disease are submitted to renal biopsy. During
2003–2005, among an overall population of 484 patients with
established renal disease, 198 had proteinuria (24 h protein excretion
4500 mg/day). Among these patients, we selected a series of
normotensive-, non-diabetic-, non-obese-, non-dyslipidemic-, and
cardiovascular events-free patients. Subjects were evaluated by
standard physical examination, chest X-ray, baseline electrocardio-
gram, two-dimensional echocardiography, and routine clinical
laboratory tests, including liver and kidney function tests and
24-h urinary protein measurements. The exclusion criteria were as
follows: hypertension (systolic BPs X140 mm Hg and/or diastolic
BPsX90 mm Hg), BMIX30 kg/m2 coronary heart disease (patients
with ischemic ST–T alterations and voltage criteria for left
ventricular hypertrophy on electrocardiogram, and with history of
revascularization or myocardial infarction), elevated liver enzymes
(aspartate aminotransferase or alanine aminotransferase levels
X40 U/l), serum creatinine levels X1.3 mg/dl, dyslipidemia (pa-
tients with total cholesterol levels higher than 200 mg/dl and
triglyceride levels higher than 150 mg/dl). After this selection
process, 78 patients were eligible for the study (42 men, 36 women,
mean age of 26.175.2 years, all Caucasians). All cases were first
referrals and at the time of the study all were off treatment. The
duration of proteinuria after initial diagnosis was not known. All
patients were submitted to renal biopsy. The patients were then
stratified into subgroups according to the severity of proteinuria.
Group I consisted of patients with proteinuria o3.5 g/day and
Group II consisted of patients with proteinuriaX3.5 g/day. Group I
included 40 patients (22 men and 18 women, age 27.174.4 years;
BMI 26.6472.14 kg/m2). Group II included 38 patients (male/
female ratio, 24/14, age 24.875.8 years; BMI 26.8671.83 kg/m2).
The control group consisted of 38 healthy subjects who were
matched to the patients with respect to age, sex, and BMI (20 men,
18 women, mean age of 26.975.9 years). They underwent
comprehensive physical and laboratory evaluation to ascertain that
they had no hypertension, metabolic, hepatic, or renal diseases. The
control subjects also had no family history of hypertension and
diabetes mellitus. All subjects gave informed consent for participat-
ing in the study. The local ethics committee of Gu¨lhane School of
Medicine approved the study.
Study design
The study had a cross-sectional design. Arterial BP was measured
three times after a 15-min resting period in the morning and mean
values were calculated for systolic and diastolic pressures in all
subjects. After an overnight fast, venous blood samples were
obtained from all subjects. In addition to routine biochemical tests
(fasting plasma glucose, blood urea, serum creatinine, total protein,
serum albumin, total cholesterol, high-density lipoprotein choles-
terol, and triglycerides), serum ADMA, insulin, and the HOMA were
performed in all participants. Additionally, to evaluate the relation-
ship between ADMA and inflammation, we also measured hsCRP in
all patients. To increase the precision of proteinuria estimates, 24-h
urine collection was performed three times and the average of three
24-h proteinuria measurements was taken as representative of each
participant 24 h protein excretion rate. In order to investigate the
relationship between proteinuria and ADMA level, we compared
serum ADMA concentrations in patients with proteinuria o3.5 g/
day to those with proteinuriaX3.5 g/day. Patients with and without
nephrotic proteinuria were also compared as stratified on the basis
of hsCRP and GFR.
Laboratory procedures
Fasting plasma glucose, blood urea, serum creatinine, total protein,
serum albumin, total cholesterol, high-density lipoprotein choles-
terol, and triglycerides were determined by enzymatic colorimetric
method with Olympus AU 600 autoanalyzer using reagents from
Olympus Diagnostics, GmbH (Hamburg, Germany). Low-density
lipoprotein cholesterol was calculated by Friedewald’s formula.
HbA1c was measured by inhibition of latex agglutination, using
a DCA 2000 analyzer (Bayer, Elkhart, IN, USA). Proteinuria
was calculated as the mean of three 24-h urine collections.
Twenty-four hour proteinuria was determined by a turbidimetric
test with trichloroacetic acid. The serum basal insulin value was
determined by the coated tube method (DPC-USA). HOMA was
computed with the formula: HOMA – insulin resistance (HOMA-
IR)¼ fasting plasma glucose (mg/dl)  immunoreactive insulin
(mIU/ml)/405.42
Measurements of ADMA and SDMA. Measurement of ADMA
and SDMA were accomplished by high-performance liquid chro-
matography, using the method described by Chen et al.43 In brief, to
1 ml serum, 20 mg of 5-sulfosalisilic acid was added and the mixture
was left in an ice-bath for 10 min. The precipitated protein was
removed by centrifugation at 2000 g for 10 min. Ten microliters of
the supernatant, which was filtered through a 0.2 mm filter, were
mixed with 100ml of derivatization reagent (prepared by dissolving
10 mg o-phtaldialdehyde in 0.5 ml of methanol, 2 ml of 0.4 M borate
buffer (pH 10.0) and 30 ml of 2-mercaptoethanol) and then injected
into the chromatographic system. Separation of ADMA was
achieved with a 150 4 mm internal diameter. Nova-pak C18
column with a particle size of 5 mm (Waters, Millipore, Milford, MA,
USA) using 50 mM sodium acetate (pH 6.8), methanol, and
tetrahydrofurane as mobile phase (A, 82:17:1; B, 22:77:1) at a flow
rate of 1.0 ml/min. The areas of peaks detected by fluores-
cent detector (Ex: 338 nm; Em: 425 nm) were used for quantification
of ADMA and SDMA levels in serum. The variability of the
method was less than 7%, and the detection limit of the assay
was 0.01mM.
hsCRP assessment. The detection interval for CRP is
0.05–35 mg/l. Serum samples were diluted with a ratio of 1/101
with the diluent solution. Calibrators, kit controls, and serum
samples were all added on each micro-well with an incubation
period of 30 min. After three washing intervals, 100 ml enzyme
conjugate (peroxidase labeled anti-CRP) was added on each micro-
well for additional 15 min incubation in room temperature in the
dark. The reaction was stopped with a stop solution and
photometric measurement was performed at the 450 nm wave-
length. The amount of serum samples was calculated as mg/l with a
graphic that was made by noting the absorbance levels of the
calibrators.
GFR assessment. GFR was calculated according to the
simplified version of the Modification of Diet in Renal Disease.
Study prediction equation formula [GFR¼ 186Pcr1.154
age0.203 1.212 (if black) 0.742 (if female)] defined by Levey.44
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Data analysis
Descriptive statistics are reported as the mean7standard deviation
for continuous variables and number (%) for nominal variables.
One-sample Kolmogorov–Smirnow test was used to evaluate the
distribution characteristics of variables. Differences between protei-
nuric patients and healthy control subjects were tested for
significance by t-test, Mann–Whitney U-test, and w2 test, as
appropriate. The relationship between paired variables was analyzed
by standard Pearsons’ correlation and by multiple regression
analysis. Differences and correlations were considered significant
at Po0.05.
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